Frequency and prognostic role of mucosal healing in patients with Crohn’s disease and ulcerative colitis after one-year of biological therapy

Table 1 Demographic and clinical characteristics of patients enrolled in the study

	CD patients (n = 41)	UC patients (n = 22)
Female/male	25/16	14/8
Mean age at diagnosis (yr)	28 (15-59)	33 (14-53)
Mean age at the beginning of biological therapy (yr)	32 (20-62)	43 (17-66)
Age at diagnosis
< 16 yr (A1)	4	2
17-40 yr (A2)	31	14
> 40 yr (A3)	6	6
Location
Ileal (L1)	6	-
Colonic (L2)	7	-
Ileocolonic (L3)	28	-
Upper GI (L4)	0	-
Proctitis	-	0
Left-sided colitis	-	14
Extensive colitis	-	8
Behaviour
Inflammatory (B1)	12	-
Stricturing (B2)	8	-
Penetrating (B3)	21	-
Perianal manifestation	23	-
Extraintestinal manifestation	26	9
Concomitant medications
Corticosteroids	32	10
Azathioprine	35	16
Surgery before the biological therapy	19	3
Previous biological therapy	13	1
Median CDAI/pMayo at the start of biological therapy	340	8
Median CRP level at the start of biological therapy (mg/L)	10	9.5
Current smokers	18	0
Appendectomy	7	0

CD: Crohn’s disease; UC: Ulcerative colitis; GI: Gastrointestinal; CRP: C-reactive protein; CDAI: Crohns disease activity index.

Table 2 Univariate regression analysis of need for retreatment with biologicals

Factor	CD-P value	UC-P value
Gender	0.98	0.57
Disease duration	0.09	0.12
Smoking status	0.99	0.37
Appendectomy	0.99	-
Location/extent	0.99	0.81
Behaviour	0.99	-
Type of anti TNF-α therapy	0.73	-
Extraintestinal manifestations	0.35	-
Steroid therapy at inclusion	0.15	0.09
Previous surgery	0.99	-
Previous biological therapy	0.38	-
Elevated CRP level	0.47	0.97
Combined immunomodulator use	0.22	0.59
Outcome of induction therapy	0.30	0.29

TNF-α: Tumor necrosis factor-α; CD: Crohn’s disease; UC: Ulcerative colitis; CRP: C-reactive protein.